Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Canada India Tech Council, in partnership with Consulate General of India (Toronto) and TheAppLabb, is proud to announce the ...

Odd Burger Corporation ("Odd Burger" or the "Company") is pleased to announce that it intends to complete a proposed non-brokered private placement (the ??"Offering") ?up to 4,000 unsecured ...

Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Pembrolizumab - branded as Keytruda - will be funded from October 1, 2024, for eligible people with advanced triple-negative ...

Shares of Trump Media & Technology Group Corp. slumped to their lowest level ever early Friday morning, the first day that ...